
iHealthScreen Inc. is a health technology company that develops innovative AI-based software for early screening, diagnosis, and prediction of retinal and systemic diseases such as Diabetic Retinopathy (DR), Age-Related Macular Degeneration (AMD), Glaucoma, stroke, heart disease, and Alzheimer's disease. Their products include AI-powered retinal image grading tools, electronic health record (EHR) solutions, telemedicine platforms, and image analyzers for retinal pathology and vessel analysis. The company aims to provide accessible, low-cost, and accurate screening in primary care settings to prevent blindness and save lives, with regulatory approvals in Europe, UK, Australia, and UAE, and FDA 510K submissions. iHealthScreen has secured significant research funding, partnerships with major hospitals like Mount Sinai, and collaborations with diabetes societies to screen millions of at-risk patients globally, positioning it as a leader in AI-driven healthcare screening and telemedicine.

iHealthScreen Inc. is a health technology company that develops innovative AI-based software for early screening, diagnosis, and prediction of retinal and systemic diseases such as Diabetic Retinopathy (DR), Age-Related Macular Degeneration (AMD), Glaucoma, stroke, heart disease, and Alzheimer's disease. Their products include AI-powered retinal image grading tools, electronic health record (EHR) solutions, telemedicine platforms, and image analyzers for retinal pathology and vessel analysis. The company aims to provide accessible, low-cost, and accurate screening in primary care settings to prevent blindness and save lives, with regulatory approvals in Europe, UK, Australia, and UAE, and FDA 510K submissions. iHealthScreen has secured significant research funding, partnerships with major hospitals like Mount Sinai, and collaborations with diabetes societies to screen millions of at-risk patients globally, positioning it as a leader in AI-driven healthcare screening and telemedicine.
Core product: iPredict — CE-certified automated retinal screening tool for DR, AMD, and glaucoma
Founded / HQ: Founded 2015; headquartered in Richmond Hill, New York, USA
Regulatory status: CE certified in Europe; FDA 510(k) submissions reported for AMD and DR
Funding highlights: Company reports $750K seed raise and ~$2.7M in NIH research awards; equity crowdfunding activity in Jun 2023
Early detection and screening of retinal and systemic diseases via AI analysis of retinal images.
2015
Health technology / Medical AI
750000.00
Company reports $750K raised as seed funding
Equity crowdfunding round listed on external profile for Jun 26, 2023
2700000.00
Company reports approximately $2.7M awarded in NIH funding
“Company reports running/pursuing an equity crowdfunding campaign on StartEngine and receiving NIH research awards”